Neuropsychiatric toxicity and cycloserine concentrations during treatment for multidrug-resistant tuberculosis

Neuropsychiatric toxicity and cycloserine concentrations during treatment for multidrug-resistant tuberculosis

Background: Cycloserine, or its structural analogue terizidone, has been associated with neuropsychiatric toxicity (psychosis, depression, and neuropathy). Prospective clinical data on the incidence of and risk factors for neuropsychiatric toxicity in TB patients treated with cycloserine are limited...

Full description

Bibliographic Details
Main Authors:	Richard Court, Chad M. Centner, Maxwell Chirehwa, Lubbe Wiesner, Paolo Denti, Nihal de Vries, Joseph Harding, Tawanda Gumbo, Gary Maartens, Helen McIlleron
Format:	Article
Language:	English
Published:	Elsevier 2021-04-01
Series:	International Journal of Infectious Diseases
Subjects:	Cycloserine Terizidone Pyridoxine Pharmacokinetics Neuropathy Neuropsychiatric
Online Access:	http://www.sciencedirect.com/science/article/pii/S120197122100206X

Similar Items

Case report on cycloserine serum levels after treatment with oral terizidone and oral cycloserine
by: Lauren Rose, et al.
Published: (2024-01-01)

Comparative Evaluation of the Efficacy and Tolerability of Chemotherapy in Patients with Drug-Resistant Pulmonary Tuberculosis Using Terizidone and Cycloserine in the Comprehensive Treatment
by: O.M. Raznatovska, et al.
Published: (2015-11-01)

FORMATION OF RESPONSE OF RATS ORGANISM ON SINGLE INFLUENCE OF TERIZIDONE - 250 MG + PYRIDOXINE HYDROCHLORIDE - 10 MG
by: K. A. Badenikova, et al.
Published: (2012-07-01)

Cycloserine induced mania
by: Ajay Kumar Bakhla, et al.
Published: (2013-01-01)

A Validated RP-HPLC Method for the Simultaneous Detection and Quantification of Pyridoxine and Terizidone in Pharmaceutical Formulations
by: Ngabo Yves Musafili, et al.
Published: (2021-12-01)

Cycloserine- and Fluoroquinolone-Induced Seizure in Multidrug-Resistance Tuberculosis (MDR-TB) Patient: A Case Report
by: Dewi Behtri Yanifitri, et al.
Published: (2024-01-01)

Adverse drug reactions due to cycloserine on the central nervous system in the multidrug-resistant tuberculosis cases: a case series
by: Sankalp Yadav, et al.
Published: (2019-11-01)

Deterioration of Cycloserine in Drug Susceptibility Testing of Mycobacterium
by: Wang R, et al.
Published: (2022-01-01)

An Evaluation of the Effects of D-Cycloserine on Operant Learning and Response Recovery
by: Consuelo San Martín, et al.
Published: (2022-11-01)

Investigation of the Effect of Cycloserine on Motor Function in a Rat Model of Parkinson’s disease
by: Reza Taherian, et al.
Published: (2017-10-01)

Minimum inhibitory concentration of cycloserine against Mycobacterium tuberculosis using the MGIT 960 system and a proposed critical concentration
by: Xiao Wu, et al.
Published: (2022-08-01)

A Review of the Actions of D-cycloserine, a Putative Nootropic Agent, at the NMDA Receptor Complex-Associated Glycine Binding Site
by: J.W Allen
Published: (2020-12-01)

Neuroimaging in Cycloserine Induced Neurotoxicity: A Rare Case Report
by: Sandeep Sharma, et al.
Published: (2018-04-01)

FORMATION OF RESPONSE OF RATS ORGANISM ON SINGLE INFLUENCE OF TERIZIDONE - 300 MG
by: K. A. Badenikova, et al.
Published: (2012-07-01)

Determination of <span style="font-variant: small-caps">d</span>-Cycloserine Impurities in Pharmaceutical Dosage Forms: Comparison of the International Pharmacopoeia HPLC–UV Method and the DOSY NMR Method
by: Damjan Makuc, et al.
Published: (2020-04-01)

High Incidence of Psychiatric Disorders Associated with Cycloserine Treatment of Multidrug-Resistant Tuberculosis Patients: A Cohort Study in Beijing, China
by: Pang Y, et al.
Published: (2022-07-01)

Cycloserine for treatment of multidrug-resistant tuberculosis: a retrospective cohort study in China
by: Li Y, et al.
Published: (2019-03-01)

Cycloserine-induced psychosis in patients with drug-resistant tuberculosis: a systematic review of case reports
by: Alonso Cotrina-Santome, et al.
Published: (2023-03-01)

Potential of D-cycloserine in the treatment of behavioral and neuroinflammatory disorders in Parkinson's disease and studies that need to be performed before clinical trials
by: Cornelius Rainer Pawlak, et al.
Published: (2012-08-01)

Cycloserine Induced Psychosis, Insomnia and Suicidal Attempts in a Young Female Patient with Pre-Extensively Drug Resistant Tuberculosis
by: Priyanka Pravinbhai Hotha, et al.
Published: (2022-12-01)

The Efficacy of Augment of D-Cycloserine and Cognitive-behavioral Therapy on Adolescent with one Type of Anxiety Disorders: A Double-blind Randomized Controlled Trial
by: Soroor Arman, et al.
Published: (2017-01-01)

Defining critical concentrations of the second line TB drugs (cycloserin and PAS), to establish drug susceptibility testing on the liquid medium of Middlebrook 7Н9
by: E. S. Dyuzhik, et al.
Published: (2016-01-01)

Assessment of the neuroprotective potential of d-cycloserine and l-serine in aluminum chloride-induced experimental models of Alzheimer’s disease: In vivo and in vitro studies
by: Özlem Özdemir Tozlu, et al.
Published: (2022-09-01)

NRX-101 (D-Cycloserine + Lurasidone) Is Active against Drug-Resistant Urinary Pathogens In Vitro
by: Michael T. Sapko, et al.
Published: (2024-03-01)

Prevalence of nontuberculous mycobacteria and high efficacy of D-cycloserine and its synergistic effect with clarithromycin against Mycobacterium fortuitum and Mycobacterium abscessus
by: Khosravi AD, et al.
Published: (2018-12-01)

Management of Adverse Events during Treatment of Tuberculosis in the Patient with Systemic Lupus Erythematosus
by: M. I. Romanova, et al.
Published: (2023-08-01)

Mass spectrometry study of noncovalent complexes formation of antibiotic cycloserine with N-acetyl-D-glucosamine and ascorbic acid
by: V. A. Pashynska, et al.
Published: (2020-07-01)

Association of schizophrenia onset age and white matter integrity with treatment effect of D-cycloserine: a randomized placebo-controlled double-blind crossover study
by: Kazuo Takiguchi, et al.
Published: (2017-07-01)

NRX-101 (D-cycloserine plus lurasidone) vs. lurasidone for the maintenance of initial stabilization after ketamine in patients with severe bipolar depression with acute suicidal ideation and behavior: a randomized prospective phase 2 trial
by: Andrew Nierenberg, et al.
Published: (2023-08-01)

Fabrication of nanocrystal forms of ᴅ-cycloserine and their application for transdermal and enteric drug delivery systems
by: Hsuan-Ang Tsai, et al.
Published: (2024-04-01)

Relationship of Brain Glutamate Response to D-Cycloserine and Lurasidone to Antidepressant Response in Bipolar Depression: A Pilot Study
by: Zhengchao Dong, et al.
Published: (2021-06-01)

Letter to Editor: Neuropsychiatric Consequences of Deep Brain Stimulation in Patients with Chronic Movement Disorders
by: Seyed Kazem Malakouti, et al.
Published: (2016-07-01)

The Neuropsychiatric Inventory-Diary Rating Scale (NPI-Diary): A Method for Improving Stability in Assessing Neuropsychiatric Symptoms in Dementia
by: Francesca Morganti, et al.
Published: (2018-09-01)

Psychiatric disorders in patients with multidrug resistant tuberculosis (MDR-TB) in Sardjito Hospital, Yogyakarta, Indonesia
by: Irwan Supriyanto, et al.
Published: (2017-08-01)

Severity of Neuropsychiatric Symptoms in Nursing Home Residents
by: Anne-Sofie Helvik, et al.
Published: (2016-01-01)

Neuropsychiatric symptoms in Alzheimer’s disease
by: J. Vegytė, et al.
Published: (2024-02-01)

Effective and Versatile Synthesis of Ginkgotoxin and Its 4′-O-Derivatives through Regioselective 4′-O-Alkylation and 4′-O-Chlorination of 3,5′-O-Dibenzylpyridoxine
by: Boshi Huang, et al.
Published: (2020-07-01)

Neuropsychiatric symptoms in patients with vascular dementia in mainland China
by: Jin Yan-ling, et al.
Published: (2015-01-01)

Sikloserin ile ilişkili mani
by: Soner Çakmak, et al.
Published: (2016-12-01)

Profiling classical neuropsychiatric biomarkers across biological fluids and following continuous lumbar puncture: A guide to sample type and time
by: Gallen Triana-Baltzer, et al.
Published: (2022-05-01)